Humana Inc. (NYSE:HUM) Shares Sold by Natixis

Natixis decreased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 68.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,013 shares of the insurance provider's stock after selling 128,455 shares during the period. Natixis' holdings in Humana were worth $14,718,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Dodge & Cox increased its stake in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC lifted its stake in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC raised its holdings in Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock valued at $729,658,000 after buying an additional 63,562 shares during the period. Finally, Invesco Ltd. grew its holdings in Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after purchasing an additional 550,692 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Shares of Humana stock traded down $3.76 during trading hours on Friday, reaching $264.07. 506,433 shares of the company's stock were exchanged, compared to its average volume of 1,743,216. The company has a market capitalization of $31.87 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The business has a fifty day moving average of $266.22 and a two-hundred day moving average of $270.36. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is presently 35.58%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Guggenheim started coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. JPMorgan Chase & Co. dropped their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Barclays raised their price objective on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a report on Friday, April 11th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus price target of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.